Skip to main content

Relative Bioavailability

6
Pipeline Programs
5
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
2 programs
2
BDA MDI 160/180 mcgPhase 11 trial
D1400147Phase 11 trial
Active Trials
NCT03934333Completed11Est. Sep 2019
NCT02359045Completed137Est. Jul 2015
TrippBio
TrippBioFL - Jacksonville
2 programs
2
PanCytoVir™Phase 11 trial
PanCytoVir™ 100 mg/mL oral suspensionPhase 11 trial
Active Trials
NCT06025318Completed14Est. Oct 2024
NCT06025344Completed14Est. Oct 2024
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ABT-333Phase 11 trial
Active Trials
NCT02052349Completed12Est. Dec 2013
Spero Therapeutics
Spero TherapeuticsMA - Cambridge
1 program
1
Tebipenem tablet formPhase 11 trial
Active Trials
NCT05296382Completed12Est. Dec 2022
Hutchmed
HutchmedChina - Hong Kong
1 program
Sulfatinib T capsulePHASE_11 trial
Active Trials
NCT03483259Completed30Est. May 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TrippBioPanCytoVir™
TrippBioPanCytoVir™ 100 mg/mL oral suspension
Spero TherapeuticsTebipenem tablet form
AstraZenecaBDA MDI 160/180 mcg
HutchmedSulfatinib T capsule
AstraZenecaD1400147
AbbVieABT-333

Clinical Trials (7)

Total enrollment: 230 patients across 7 trials

NCT06025318TrippBioPanCytoVir™

An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers

Start: Sep 2024Est. completion: Oct 202414 patients
Phase 1Completed
NCT06025344TrippBioPanCytoVir™ 100 mg/mL oral suspension

A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml)

Start: Sep 2024Est. completion: Oct 202414 patients
Phase 1Completed
NCT05296382Spero TherapeuticsTebipenem tablet form

Bioavailability of Tebipenem (SPR994) Crushed Tablet

Start: Apr 2022Est. completion: Dec 202212 patients
Phase 1Completed
NCT03934333AstraZenecaBDA MDI 160/180 mcg

A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)

Start: May 2019Est. completion: Sep 201911 patients
Phase 1Completed
NCT03483259HutchmedSulfatinib T capsule

To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers

Start: Apr 2018Est. completion: May 201830 patients
Phase 1Completed
NCT02359045AstraZenecaD1400147

Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions

Start: Feb 2015Est. completion: Jul 2015137 patients
Phase 1Completed
NCT02052349AbbVieABT-333

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Start: Nov 2013Est. completion: Dec 201312 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.